Intrapleural hemocoagulase Bothrops atrox and early outcomes after VATS for stage IA non-small cell lung cancer.
[BACKGROUND] Hemocoagulase Bothrops atrox (HBA) is used to reduce surgical bleeding, but its impact on postoperative coagulation after video-assisted thoracoscopic surgery (VATS) remains unclear.
- 95% CI 0.11-0.45
- OR 0.35
APA
Ruan Y, Xue H, et al. (2026). Intrapleural hemocoagulase Bothrops atrox and early outcomes after VATS for stage IA non-small cell lung cancer.. Frontiers in medicine, 13, 1774067. https://doi.org/10.3389/fmed.2026.1774067
MLA
Ruan Y, et al.. "Intrapleural hemocoagulase Bothrops atrox and early outcomes after VATS for stage IA non-small cell lung cancer.." Frontiers in medicine, vol. 13, 2026, pp. 1774067.
PMID
42040554
Abstract
[BACKGROUND] Hemocoagulase Bothrops atrox (HBA) is used to reduce surgical bleeding, but its impact on postoperative coagulation after video-assisted thoracoscopic surgery (VATS) remains unclear. We evaluated the effects of intrapleural HBA on coagulation profiles and early recovery in stage IA non-small cell lung cancer (NSCLC).
[METHODS] We retrospectively analyzed 442 stage IA NSCLC patients undergoing VATS, allocated to HBA ( = 92) or non-HBA ( = 350) groups. The primary outcome was postoperative coagulation; secondary outcomes were length of stay and postoperative complications. Baseline characteristics were balanced using inverse probability of treatment weighting (IPTW), followed by multivariable analyses.
[RESULTS] After IPTW adjustment, intrapleural HBA was associated with a longer prothrombin time (PT; 12.83 ± 0.99 vs. 12.31 ± 1.50 s; = 0.28, 95% CI 0.11-0.45, = 0.001) and lower fibrinogen (FIB) levels (322.06 ± 96.68 vs. 353.52 ± 122.65 mg/dL; = -33.33, 95% CI - 48.46 to -18.20, < 0.001), while activated partial thromboplastin time and thrombin time did not differ significantly. In the IPTW-weighted cohort, HBA use was associated with a lower incidence of postoperative complications (6.5% vs. 12.0%; OR = 0.35, 95% CI 0.19-0.63, = 0.001) and a shorter postoperative hospital stay ( = -2.06, 95% CI - 2.61 to -1.50, < 0.001).
[CONCLUSION] Intrapleural HBA injection in stage IA NSCLC undergoing VATS is associated with modest alterations in coagulation (prolonged PT and reduced FIB) and improved early outcomes, including fewer complications and shorter hospitalization. Prospective studies are warranted to confirm these findings.
[METHODS] We retrospectively analyzed 442 stage IA NSCLC patients undergoing VATS, allocated to HBA ( = 92) or non-HBA ( = 350) groups. The primary outcome was postoperative coagulation; secondary outcomes were length of stay and postoperative complications. Baseline characteristics were balanced using inverse probability of treatment weighting (IPTW), followed by multivariable analyses.
[RESULTS] After IPTW adjustment, intrapleural HBA was associated with a longer prothrombin time (PT; 12.83 ± 0.99 vs. 12.31 ± 1.50 s; = 0.28, 95% CI 0.11-0.45, = 0.001) and lower fibrinogen (FIB) levels (322.06 ± 96.68 vs. 353.52 ± 122.65 mg/dL; = -33.33, 95% CI - 48.46 to -18.20, < 0.001), while activated partial thromboplastin time and thrombin time did not differ significantly. In the IPTW-weighted cohort, HBA use was associated with a lower incidence of postoperative complications (6.5% vs. 12.0%; OR = 0.35, 95% CI 0.19-0.63, = 0.001) and a shorter postoperative hospital stay ( = -2.06, 95% CI - 2.61 to -1.50, < 0.001).
[CONCLUSION] Intrapleural HBA injection in stage IA NSCLC undergoing VATS is associated with modest alterations in coagulation (prolonged PT and reduced FIB) and improved early outcomes, including fewer complications and shorter hospitalization. Prospective studies are warranted to confirm these findings.
같은 제1저자의 인용 많은 논문 (5)
- Assessment of pneumonitis in patients with lung cancer undergoing radioimmunotherapy and immune checkpoint inhibitor rechallenge.
- Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies.
- Erianin suppresses lung adenocarcinoma by modulating miR-494-3p/MAPK/ERK pathway.
- Risk factor of pneumonitis resulting from thoracic chemoradiotherapy combined with immunotherapy in lung cancer: A meta-analysis and systematic review.
- Upregulation of PD-L1 and MMP9 in HR-HPV-associated cervical squamous cell carcinoma: correlation with histological progression and immune microenvironment remodeling.